Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease‐Activated Receptor Pathway
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease‐Activated Receptor Pathway
Authors
Keywords
-
Journal
Journal of the American Heart Association
Volume 8, Issue 8, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-04-06
DOI
10.1161/jaha.119.012195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin
- (2018) Hiroaki Ichikawa et al. International Heart Journal
- Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
- (2017) Xiaoxi Yao et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic NephropathyHighlights
- (2016) Yuji Oe et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With WarfarinClinical Perspective
- (2016) Christopher B. Fordyce et al. CIRCULATION
- Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure
- (2016) Tomohiro Tanno et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis
- (2016) Panagiotis Flevaris et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry
- (2015) Yasuhiro Hamatani et al. PLoS One
- A Long-Term High-Fat/High-Sucrose Diet Promotes Kidney Lipid Deposition and Causes Apoptosis and Glomerular Hypertrophy in Bama Minipigs
- (2015) Li Li et al. PLoS One
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
- (2013) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Plasminogen activator inhibitor-1 in kidney pathology
- (2013) SYLWIA MAŁGORZEWICZ et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
- (2012) Jonas Bjerring Olesen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vitamin K-Antagonists Accelerate Atherosclerotic Calcification and Induce a Vulnerable Plaque Phenotype
- (2012) Leon J. Schurgers et al. PLoS One
- Warfarin-Related Nephropathy Modeled by Nephron Reduction and Excessive Anticoagulation
- (2011) K. Ware et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban: A New Oral Factor Xa Inhibitor
- (2010) Elisabeth Perzborn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipopolysaccharide-Triggered Acute Aggravation of Mesangioproliferative Glomerulonephritis through Activation of Coagulation in a High IgA Strain of ddY Mice
- (2009) Makiko Shimosawa et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Relationship of Plasma Renin With a Prothrombotic State in Hypertension: Relevance for Organ Damage
- (2008) L. A. Sechi et al. AMERICAN JOURNAL OF HYPERTENSION
- Mechanisms of Thrombus Formation
- (2008) Bruce Furie et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now